CEO and President Joe Payne outlined the company’s current focus on messenger RNA (mRNA) therapeutics, emphasizing a leaner operating profile and a near-term set of clinical and regulatory milestones ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback